Preparing healthcare companies for success
in the value-based economy

Ryan Walsh: 2020 PharmaVOICE 100

read article>


Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.

more >


Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.

more >

Our Solutions

News and Events

High Priced Drugs for Rare Disease: Leading US Payers Discuss Cost Concerns, Value-Based Contracts and ICER

by Cathy Kelly

Expert perspectives on reimbursement for high-cost therapies, both chronic and curative, were discussd at the recent Biotechnology Innovation Organization virtual international convention. The panel discussion, moderated by Real Endpoints CEO Jeff Berkowitz, focused on pharmacy benefit manager and payer concerns with affordability, the role of patient advocacy, value-based purchasing, and ICER value assessments

June 14, 2020

Pink Sheet

read full article >

Rare Disease Therapies are No Longer Rare: Can the US Healthcare Reimbursement System Handle Chronic Treatments for Orphan Diseases

Moderator: Jeffrey Berkowitz, CEO and Director

Real Endpoints

Real Endpoints is excited to be moderating this important panel on reimbursement of chronic rare and orphan disease therapies at the upcoming BIO International Digital Convention

June 8, 2020 -
June 12, 2020

event >

What Your Board Needs to Know About Market Access and Oncology: A Webinar for Top Management

Panelist: Jeffrey Berkowitz, CEO and Director
Roger Longman, Founder and Chairman

Real Endpoints

CELLO Health BioConsulting Webinar with Real Endpoints: In this senior executive webinar, we’ll give a boardroom presentation, and take your questions, on cancer’s unique payer situation and its stability — or instability. Our focus: how the informed biotech executive team manages early (and late) clinical and commercial development to ensure success not just with the FDA but in what may be a very different and less favorable reimbursement environment

May 19, 2020
12:00pm ET

event >

Don’t Waste this Crisis: Solving the Patient Cost-Share Problem

by Jeff Berkowitz

Insurers have been playing a beneficial role in the pandemic crises by expanding access to, and cutting patient costs of, Covid-related diagnosis and treatment. How might insurer’s apply the COVID-19 cost-share initiatives to other population-wide problems?

April 15, 2020

Timmerman Report

news >

Recent Insights

view archive >

June 30, 2020

Opportunity Offered by a Good Crisis: COVID-19 IMPACT ON INNOVATIVE PRICING MODELS

An interview with Roger Longman, Cofounder and Chairman of Real Endpoints LLC in which he discusses innovative and value-based contracting models currently in use and reflects on the downstream effects of innovative pricing on patients and their out-of-pocket costs.

read full interview >

April 20, 2020

Drug Coverage in the Pandemic: US Payers Shift Focus From Costs To Access, For Now

US payers are concentrating on ensuring access to health care during the COVID-19 pandemic, which has led them to relax, postpone or waive some formulary and coverage policies to avoid disruptions in patient access to prescription drugs.

read full insights article >